Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Appointed director
Consulting agrmnt
|
|
Icagen, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/30/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/02/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/20/2018 |
8-K
| Amended existing or entered into new employment agreement with an officer |
| 10/01/2018 |
8-K/A
| Quarterly results |
| 09/06/2018 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...|
Docs:
|
"Warrant to Purchase Common Stock issued to Perceptive Credit Holdings II, LP",
"Second Amended and Restated Warrant issued to GPB Debt Holdings II, LLC",
"Credit Agreement and Guaranty, by and among, Icagen, Inc., Caldera Discovery, Inc., XRpro Sciences, Inc., Icagen Corp., the banks and other financial institutions from time to time party thereto, as Lenders, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders",
"Credit Agreement and Guaranty, by and among, Icagen-T, Inc., Icagen, Inc., Caldera Discovery, Inc., XRpro Sciences, Inc., Icagen Corp., the banks and other financial institutions from time to time party thereto, as Lenders, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders",
"Security Agreement, by and among Icagen, Inc., certain of the Icagen, Inc’ s subsidiaries from time to time parties thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders",
"Security Agreement, by and among Icagen-T, Inc., Icagen, Inc., certain of Icagen, Inc.’ s subsidiaries from time to time parties thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the Lenders" |
|
| 08/31/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/15/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/17/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 06/05/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 05/01/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/09/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/11/2017 |
8-K
| Quarterly results |
| 06/21/2017 |
8-K
| Form 8-K - Current report |
| 05/17/2017 |
8-K
| Form 8-K - Current report |
| 04/14/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 07/18/2016 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Master Services Agreement between Icagen-T, Inc. and Sanofi US Services Inc. dated July 15, 2016*",
"Master Services Agreement between Icagen-T, Inc. and Sanofi US Services Inc. dated July 15, 2016*",
"Deed of Trust",
"Deed of Sale",
"Deed of Sale",
"Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. and Pfizer Research (NC), Inc.",
"Icagen Acquisition of Sanofi Arizona Research Facility Complete" |
|
| 07/07/2016 |
8-K
| Form 8-K - Current report |
| 06/30/2016 |
8-K
| Form 8-K - Current report |
| 05/20/2016 |
8-K
| Form 8-K - Current report |
| 05/03/2016 |
8-K
| Form 8-K - Current report |
| 02/25/2016 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/29/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/02/2015 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/31/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 07/02/2015 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhi...|
Docs:
|
"Asset Purchase Agreement and Collaboration Agreement between XRpro Sciences, Inc. and Icagen, Inc.",
"Master Services Agreement between XRpro Sciences, Inc. and Pfizer, Inc. (1) (2)",
"Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D “New” Icagen to Offer Pharma and Biotech Companies Expert Services and Technology Access, while Continuing Pfizer Two-Year Collaboration Cambridge, MA and Durham, NC : XRpro Sciences, Inc. today announced its acquisition of assets related to the ion channel biology platform from Pfizer Inc. that had previously been obtained as part of Pfizer’ s 2011 acquisition of Icagen, Inc. XRPro Sciences also acquired all of Pfizer’ s rights to the “Icagen” name and trademark. XRPro Sciences is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen’ s industry-leading scientific expertise and extensiv..." |
|
| 03/26/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 02/25/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 02/03/2015 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 01/07/2015 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 12/04/2014 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 11/17/2014 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Employment Agreement, by and between Richard Cunningham and the Company",
"XRpro Appoints Richard Cunningham President and CEO Cambridge, MA—November 17, 2014 – Caldera Pharmaceuticals, Inc., d/b/a XRpro , a provider of a unique platform for drug discovery and development services which feature high throughput transporter and ion channel assays for the pharmaceutical industry, today announced the appointment of Richie Cunningham as its President and CEO effective November 24, 2014. Tim Tyson, Acting CEO and Chairman of XRpro commented, “I believe that Richie’ s extensive pharmaceutical experience and success throughout his career commercializing products and leading teams brings to XRpro the insight, knowledge and experience needed to expand and accelerate our growth.” He continued, “I fully expect that Richie’ s sales and marketing expertise will complement our ..." |
|
| 09/26/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/09/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|